Qiming Venture Partners has led a significant financing round for Sany Hydrogen Energy, underscoring confidence in the company's capabilities and commitment to advancing green hydrogen solutions in a rapidly evolving energy landscape.

Target Company Overview

Jiangsu Tiga Medical Co., Ltd. (300347.SZ, 03347.HK), an investment of Qiming Venture Partners, has achieved the highest AAA rating in the latest Environmental, Social, and Governance (ESG) ratings published by Morgan Stanley Capital International (MSCI). This notable accomplishment marks the company's inaugural receipt of the top ESG rating from MSCI, positioning it among the global leaders in ESG practices and establishing it as a benchmark enterprise in its industry.

Tiga Medical has recently validated its greenhouse gas reduction targets through the Science-Based Targets initiative (SBTi). The company actively fulfills its environmental responsibilities by enhancing its environmental management system, strengthening emissions and resource use management, and implementing digital platforms and green office practices. In terms of social responsibility, Tiga Medical promotes digital transformation, employing AI technology to optimize clinical trial processes, safeguarding women's employee rights, and setting diversity targets. The company engages in various philanthropic initiatives through the Hangzhou Tiga Medical Public Welfare Foundation, which focuses on supporting medical, education, and poverty alleviation efforts and contributes to rural revitalization.

Industry Overview in China

The healthcare and life sciences sector in China is rapidly evolving, driven by increasing demand for innovative medical solutions and advancements in technology. With a growing aging population and a rise in chronic diseases, the need f

View Source

Similar Deals

启明创投 微滔生物科技(上海)有限公司

2025

Seed Stage Proprietary & Advanced Pharmaceuticals China
济峰资本 依利特科技

2024

Seed Stage In-Vivo Diagnostic & Testing Substances China
昆仑资本 和泽科技

2023

Seed Stage Bio Medical Devices China
光点资本 红瑞生物

2023

Seed Stage Biotechnology & Medical Research (NEC) China
Adicon Holdings Limited Crown Bioscience Inc.

2026

Other Biotechnology & Medical Research (NEC) China

启明创投

invested in

蔚程医药有限公司

in 2025

in a Seed Stage deal

Disclosed details

Transaction Size: $142M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert